Stay updated on Copanlisib and Nivolumab in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Copanlisib and Nivolumab in Lymphoma Clinical Trial page.

Latest updates to the Copanlisib and Nivolumab in Lymphoma Clinical Trial page
- Check6 days agoChange DetectedAdded the condition term Malignant lymphoma, large B-cell, diffuse to the study's conditions. Included a new Resources entry linking to the Genetic and Rare Diseases Information Center.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedRevision: v3.5.0. No obvious changes to the study details or user-facing content are visible compared to the previous version.SummaryDifference0.0%

- Check27 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check56 days agoChange DetectedAdded Revision: v3.4.2; removed the funding notice and Revision: v3.4.1 text. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check63 days agoChange DetectedThe page now shows a government funding status notice and a revision update (v3.4.1). The previous revision (v3.4.0) was removed.SummaryDifference0.4%

- Check70 days agoChange DetectedGlossary display is now shown by default and page metadata labels were updated to Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0, replacing Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4; this is a minor UI/metadata update that does not affect study data or content, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Copanlisib and Nivolumab in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Copanlisib and Nivolumab in Lymphoma Clinical Trial page.